Needham & Company LLC initiated coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report released on Friday, TipRanks reports. The brokerage issued a buy rating and a $36.00 price target on the specialty pharmaceutical company’s stock.
COLL has been the subject of a number of other research reports. BidaskClub cut Collegium Pharmaceutical from a hold rating to a sell rating in a research report on Tuesday, June 9th. Guggenheim initiated coverage on Collegium Pharmaceutical in a report on Tuesday, May 26th. They issued a neutral rating for the company. Zacks Investment Research lowered Collegium Pharmaceutical from a hold rating to a sell rating in a research note on Wednesday, April 29th. Finally, William Blair reaffirmed a buy rating on shares of Collegium Pharmaceutical in a research report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Collegium Pharmaceutical has an average rating of Hold and a consensus price target of $31.43.
Shares of NASDAQ COLL opened at $17.14 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 0.92 and a quick ratio of 0.85. The stock has a market capitalization of $585.50 million, a P/E ratio of -45.11, a price-to-earnings-growth ratio of 0.51 and a beta of 1.07. Collegium Pharmaceutical has a 1-year low of $10.01 and a 1-year high of $25.59. The business has a fifty day moving average price of $20.09 and a 200 day moving average price of $20.29.
In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 70,676 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $21.53, for a total value of $1,521,654.28. Following the sale, the chief executive officer now directly owns 204,515 shares of the company’s stock, valued at $4,403,207.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael Thomas Heffernan sold 19,254 shares of Collegium Pharmaceutical stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $21.63, for a total transaction of $416,464.02. Following the completion of the sale, the director now directly owns 99,670 shares in the company, valued at approximately $2,155,862.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,353 shares of company stock worth $2,211,493. Insiders own 8.08% of the company’s stock.
Several institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in Collegium Pharmaceutical by 13.4% during the 1st quarter. Janus Henderson Group PLC now owns 5,103,966 shares of the specialty pharmaceutical company’s stock worth $83,347,000 after purchasing an additional 601,617 shares during the last quarter. Camber Capital Management LP purchased a new position in shares of Collegium Pharmaceutical in the first quarter worth about $32,660,000. Franklin Resources Inc. boosted its position in Collegium Pharmaceutical by 3.4% during the first quarter. Franklin Resources Inc. now owns 1,829,772 shares of the specialty pharmaceutical company’s stock worth $29,881,000 after acquiring an additional 59,620 shares during the last quarter. Perceptive Advisors LLC boosted its position in Collegium Pharmaceutical by 268.3% during the first quarter. Perceptive Advisors LLC now owns 1,551,722 shares of the specialty pharmaceutical company’s stock worth $25,339,000 after acquiring an additional 1,130,450 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Collegium Pharmaceutical by 67.6% during the 4th quarter. Renaissance Technologies LLC now owns 1,252,328 shares of the specialty pharmaceutical company’s stock valued at $25,773,000 after acquiring an additional 505,128 shares in the last quarter.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.